Compare General Motors Company (GM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Summit Therapeutics Inc — how do they compare? General Motors Company trades at $89.6 (market cap $78.40B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: General Motors Company is far larger — about 6.5× Summit Therapeutics Inc's market cap, and General Motors Company pays a 0.81% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GM | SMMT | |
|---|---|---|
Market Cap | $78.40B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $26.98 |
52-Week Low | $54.16 | $12.55 |
Enterprise Value | $181.38B | $11.39B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.19, down 0.88% on the day, with strong technical momentum showing bullish moving average signals. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.57 exceeding the $3.19 estimate. Recent developments include a $4.5 billion parts supply agreement to mitigate future disruptions and a renewed 20-year joint venture with China's SAIC Motor. Analyst consensus remains strongly positive with a $108.82 price target representing 25% upside potential.
GM presents a compelling investment case with attractive valuation metrics including P/S of 0.45 and EV/EBITDA of 10.35, though profitability metrics remain challenged with net margin at 1.05%. Key risks include declining profit margins from 6.33% in 2022 to 1.45% in 2025, high debt levels with debt-to-asset ratio of 46.79%, and ongoing supply chain challenges in the automotive sector.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
